Evidence map›Paper›PMID 42903938›Full record

ArticlehLife2025

Tip optofluidic immunoassay: Evaluating COVID-19 antibody protection with 1 μL fingertip blood.

Xiaotian Tan, Yujuan Chai, Ruihan Li, Binmao Zhang, Hao Li, Jie Zhang, Tianen Zhu, Weishu Wu, Lixiang An, Shi Hu and 22 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in hLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Xiaotian TanInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China.
Yujuan ChaiDepartment of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Guangdong, China.
Ruihan LiInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China.
Binmao ZhangInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China.
Hao LiInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China.
Jie ZhangBeijing Key Laboratory of Monoclonal Antibody Research and Development, Sino Biological Inc., Beijing, China.
Tianen ZhuEmergency Department, Shenzhen University General Hospital, Shenzhen University, Guangdong, China.
Weishu WuDepartment of Biomedical Engineering, University of Michigan, Michigan, USA.
Lixiang AnNational Innovation Center for Advanced Medical Devices, Guangdong, China.
Shi HuInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China.
Bin YangBeijing Key Laboratory of Monoclonal Antibody Research and Development, Sino Biological Inc., Beijing, China.
Li WangBeijing Key Laboratory of Monoclonal Antibody Research and Development, Sino Biological Inc., Beijing, China.
Zhenqiu CaoInstitute of Zoology, Chinese Academy of Sciences, Beijing, China.
Hongjiu ZhangInstitute of Zoology, Chinese Academy of Sciences, Beijing, China.
Peng WangChangping Laboratory, Beijing, China.
Lingling YuChangping Laboratory, Beijing, China.
Shan YinChangping Laboratory, Beijing, China.
Xingyu LiChangping Laboratory, Beijing, China.
Fei ShaoChangping Laboratory, Beijing, China.
Jianheng HuangInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China.
Jinze LiInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China.
Fan YangState Key Laboratory of Biomedical Imaging Science and System, Guangdong, China.
Chao ZhaoInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China.
Jiajia GuoInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China.
Lin ZengInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China.
Dong LiangInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China.
Zhengting ZouInstitute of Zoology, Chinese Academy of Sciences, Beijing, China.
Hairong ZhengInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China.
Xudong FanDepartment of Biomedical Engineering, University of Michigan, Michigan, USA.
Liangzhi XieBeijing Key Laboratory of Monoclonal Antibody Research and Development, Sino Biological Inc., Beijing, China.
Yunlong CaoChangping Laboratory, Beijing, China.
Hui YangInstitute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infectious diseases such as coronavirus disease 2019 (COVID-19) continue to pose significant global health challenges. Effective management of reinfection risks depends on sustained levels of binding and neutralizing antibodies. However, conventional methods-such as enzyme-linked immunosorbent assays (ELISA) and virus neutralization tests (VNT)-are limited by complex workflows, long assay durations, and high sample volume requirements, making them less suitable for routine, decentralized, or time-sensitive surveillance. This study presents a custom-developed tip optofluidic immunoassay (TOI) platform that enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood. The system integrates batch-fabricated microfluidic immunoreactors with a portable chemiluminescent imaging station, completing both binding and neutralization capability assessments within 40 min. TOI achieves a broad dynamic range (3-4 orders of magnitude), high signal-to-noise ratio (∼10,000), and excellent sensitivity for immunoglobulin G (IgG) detection. A renovated version of the rapid

Indexed as

antibody protection assessmentbiosensingcoronavirus disease 2019 (COVID-19)fingertip bloodoptofluidic immunoassay

Identifiers

PMID42903938
PMCPMC13681586

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.